Technology offers

We commercialize innovative technologies which poses high potential to meet the needs of scientists of the modern economy. Our main source of inventions are Institutes of consortium Biocentrum Ochota, highly experienced in conducting research at the highest level. Presented below solutions exhibit high commercial potential and delivers solutions for competetive advantage of companies.

Enzymes for biotechnology and industry

Healthcare and pharmacy

Title: Tools and methods useful in characterizing the immuntotoxic activity of xenobiotic substances.

Inventors: Ulleras Erik; Nilsson Gunnar; Ringerike Tove; Vandebriel Robert Jan; Walczak-Drzewiecka Aurelia; Al-Nedawi Khalid; Wyczolkowska Janina; Stepnik Maciej; Arkusz Joanna; Rydzynski Konrad; Adamczewska Violetta; Trzaska Dominka; Olszewski Maciej; Bialek-Wyrzykowska Urszula; Dastych Jaroslaw; Lovik Martinus.(IIMCB)

Fluorescent Cell Chip (FCC) is a novel cost-efficient HTS screen for flagging potential immunomodulators and/or immunotoxicants in early phases of drug development. This assay is utilizing the EL-4 murine lymphoid cell line stably transfected with transgenes coding for fluorescent proteins under the control of several cytokine gene promoters. The FCC technology has been developed by the international research consortium led by the IIMCB in Warsaw. Proteon Pharmaceuticals S. A. is a research spin off company that has further developed the FCC technology into fully automated high throughput screening platform. As a result FCC can be used in the preclinical research for screening chemical libraries to discover novel immunomodulatory compounds that could become candidates for novel antiinflammatory, antiallergic and anticancer drugs.

Title: A virus-like particle vector for delivery of pharmaceutical agents, a process for the manufacture thereof, its uses and a pharmaceutical composition.

Inventors: Ewa Szołajska, Jadwiga Chroboczek, Monika Żochowska,( IBB PAS)

Title: Virus-like particle vector as a polyvalent platform for intracellular delivery of high-molecular-weight therapeutic substances, method for generating a virus like particle vector and use a virus like particle vector and a pharmaceutical composition containing said virus- like particle vector.

Inventors: Jadwiga Chroboczek, Ewa Szołajska, Antonina Naskalska, (IBB PAS)

The embodiment of both inventions is a virus-like particle vector - an adenoviral dodecahedron (Dd) built from Adenovirus pentons or penton base protein, responsible for virus intracellular penetration. Dd has extraordinary cell entry properties, up to 300000 particles can be observed in one cell in vitro.

The recombinant Dd is obtained with high yield in insect cells in the baculovirus system. The purification protocol consists of a simple two-step procedure. The vector is intended for the delivery of active agents into mammalian cells. According to the method of the invention, the therapeutic substances/agents may be encapsulated and attached/linked to Dd covalently or noncovalently by means of the universal linker.

Inventions allow for production of human or animal vaccines, delivery of antibodies, antitumour proteins, antitumour agents, nucleic acids, enzymes and immunosuppressive agents, as well as proteins/peptides and lipids determining specific tissue tropism or nucleic acids, to mammalian cells.

Title: Medical application of lipid derivatives of dopamine and the methods of their production.

Inventors: Mieczyslaw Pokorski, Agnieszka Rekawek, Dominika Zając, Zbigniew Czarnocki, Edmund Przegalinski, Jolanta Konieczny, Piotr Roszkowski

The invention is a potential medication for treatment or prophylaxis of neurodegenerative disorders with a deficient dopamine content or dopaminergic transmission induced by disease or genetic factors. These lipophilic compounds penetrate biological barriers, diminish muscle rigidity and are biologically much more stable than dopamine is. Compounds may become an alternative to currently used dopamine prodrugs.

Enzymes for biotechnology and industry

Title: A method of proteolisys, a peptidase, a composytion for use as a bacteriostatic or bactericidal agent, a kit and the uses of the acive form of LytM of S. Aureus or a derivative thereof.

Inventors: Izabela Sabała, Matthias Bochtler, (IIMCB)

The subject of the offer is the recombinant catalytic domain of peptidoglycan hydrolase LytM from Staphylococcus aureus, which:

- lyses staphylococcal cells with high efficiency,

- sustains high activity in a wide range of temperatures (0-30ºC),

- is unusually active in low conductivity conditions, including pure water,

- is very stable,

- can be produced in high yield and simply purified at low costs.

The enzyme can be very useful in laboratory applications, for decontamination of large surfaces as well as in industrial scale, e. g. to control microbial quality of food.

Tools for biotechnology

Title: Method of hydrolysis of peptide bond.

Inventors: Wojciech Bal, Edyta Kopera, Artur Krężel, Aleksandra Wysłouch-Cieszyńska (IBB PAS)

The invention concerns the method of hydrolysis of a dedicated peptide bond in a recombinant protein. The method of the invention is executed by adding Ni(II) salt to a solution of the said protein, by means of its selective interaction with the designed oligopeptide sequence, directly following the last C-terminal residue of the said protein. The method of the invention serves as a tool of removal of an affinity tag from this protein, following the process of affinity purification of the said protein on a support. According to the method of the invention, the protein purification can be executed with high efficacy and excellent selectivity, and a native protein is obtained.

Inventions allow for production of recombinant proteins under a variety of additives, including low and high salt, denaturing agents, ionic and non-ionic detergents, and reducing agents. It yields proteins of very high purity, free of proteases and at a low unit costs. The method of the invention can be executed in solution or on a support, which adds versatility to its usage.